Home > Insider Trading > Filing (0001140361-17-018048)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1444380	Nevro Corp	NVRO	Surgical & Medical Instruments & Apparatus (3841)	562568057

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1613689	Rami Elghandour	C/O Nevro Corp. 1800 Bridge Parkway Redwood City CA 94065	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-05-01	10,000	$3.60	105,224	No	4	M	Direct
Common Stock	Disposition	2017-05-01	10,000	$95.03	95,224	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2017-05-01	10,000	$0.00	10,000	$3.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
65,051		2023-05-14	No	4	M	Direct

Footnotes

Includes 94,739 restricted stock units.
The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.36, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The option, representing the right to purchase 88,207 shares of the Issuer's common stock, vests and becomes exercisable in respect to 1/48th of the original number of shares subject to the option on each monthly anniversary measured from May 15, 2013 (the "Vesting Commencement Date"), such that 100% of the shares underlying the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.